3 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Rebastinib, Paclitaxel - Locally Advanced or Metastatic Solid Tumor | Phase 1 / Phase 2 | Terminated | Deciphera Pharmaceuticals, LLC | 177 | 2018-10-25 | 2024-12-27 |
Ovarian Neoplasms (3) · Endometrial Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma, Mucinous (1) · Breast Neoplasms (1) · Cystadenocarcinoma, Serous (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1) · Uterine Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Adnexal Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Complex and Mixed (3) · Neoplasms, Connective and Soft Tissue (3) · Ovarian Diseases (3)
Axitinib (1) · Carboplatin (1) · DCC-2036 (1) · Fulvestrant (1) · Paclitaxel (1) · rebastinib (1) · ribociclib (1)
Blueprint Medicines Corporation (1) · Deciphera Pharmaceuticals, LLC (1) · Incyte Corporation (1)
United Kingdom (2) · United States (2) · Italy (1)
2023 (1)